174 related articles for article (PubMed ID: 22682917)
1. The Liege Acromegaly Survey (LAS): a new software tool for the study of acromegaly.
Petrossians P; Tichomirowa MA; Stevenaert A; Martin D; Daly AF; Beckers A
Ann Endocrinol (Paris); 2012 Jun; 73(3):190-201. PubMed ID: 22682917
[TBL] [Abstract][Full Text] [Related]
2. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size.
Bevan JS; Atkin SL; Atkinson AB; Bouloux PM; Hanna F; Harris PE; James RA; McConnell M; Roberts GA; Scanlon MF; Stewart PM; Teasdale E; Turner HE; Wass JA; Wardlaw JM
J Clin Endocrinol Metab; 2002 Oct; 87(10):4554-63. PubMed ID: 12364434
[TBL] [Abstract][Full Text] [Related]
3. Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acromegaly Registry.
Fieffe S; Morange I; Petrossians P; Chanson P; Rohmer V; Cortet C; Borson-Chazot F; Brue T; Delemer B;
Eur J Endocrinol; 2011 Jun; 164(6):877-84. PubMed ID: 21464140
[TBL] [Abstract][Full Text] [Related]
4. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly.
Colao A; Ferone D; Marzullo P; Cappabianca P; Cirillo S; Boerlin V; Lancranjan I; Lombardi G
J Clin Endocrinol Metab; 2001 Jun; 86(6):2779-86. PubMed ID: 11397887
[TBL] [Abstract][Full Text] [Related]
5. Acromegaly and pregnancy: a retrospective multicenter study of 59 pregnancies in 46 women.
Caron P; Broussaud S; Bertherat J; Borson-Chazot F; Brue T; Cortet-Rudelli C; Chanson P
J Clin Endocrinol Metab; 2010 Oct; 95(10):4680-7. PubMed ID: 20660047
[TBL] [Abstract][Full Text] [Related]
6. [Outcome of somatostatin analogue treatment in acromegaly].
Mondok A; Tóth M; Patócs A; Szücs N; Igaz P; Pusztai P; Czirják S; Beko G; Gláz E; Rácz K; Tulassay Z
Orv Hetil; 2009 Aug; 150(31):1457-62. PubMed ID: 19617182
[TBL] [Abstract][Full Text] [Related]
7. Clinical-biochemical correlations in acromegaly at diagnosis and the real prevalence of biochemically discordant disease.
Mercado M; Espinosa de los Monteros AL; Sosa E; Cheng S; Mendoza V; Hernández I; Sandoval C; Guinto G; Molina M
Horm Res; 2004; 62(6):293-9. PubMed ID: 15542931
[TBL] [Abstract][Full Text] [Related]
8. A follow-up of 130 patients with acromegaly in a single centre.
Bolanowski M; Zatonska K; Kaluzny M; Zielinski G; Bednarek-Tupikowska G; Bohdanowicz-Pawlak A; Daroszewski J; Szymczak J; Podgorski JK
Neuro Endocrinol Lett; 2006 Dec; 27(6):828-32. PubMed ID: 17187024
[TBL] [Abstract][Full Text] [Related]
9. The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly.
Carmichael JD; Bonert VS; Mirocha JM; Melmed S
J Clin Endocrinol Metab; 2009 Feb; 94(2):523-7. PubMed ID: 19033371
[TBL] [Abstract][Full Text] [Related]
10. Changing patterns of insulin-like growth factor-I and glucose-suppressed growth hormone levels after pituitary surgery in patients with acromegaly.
Espinosa-de-los-Monteros AL; Mercado M; Sosa E; Lizama O; Guinto G; Lopez-Felix B; Garcia O; Hernández I; Ovalle A; Mendoza V
J Neurosurg; 2002 Aug; 97(2):287-92. PubMed ID: 12186455
[TBL] [Abstract][Full Text] [Related]
11. Pure endoscopic transsphenoidal surgery for treatment of acromegaly: results of 67 cases treated in a pituitary center.
Gondim JA; Almeida JP; de Albuquerque LA; Gomes E; Schops M; Ferraz T
Neurosurg Focus; 2010 Oct; 29(4):E7. PubMed ID: 20887132
[TBL] [Abstract][Full Text] [Related]
12. Octreotide as primary therapy for acromegaly.
Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
[TBL] [Abstract][Full Text] [Related]
13. Twelve years of the Spanish acromegaly registry: a historical view of acromegaly management in Spain.
Sesmilo G; Webb SM;
Endocrinol Nutr; 2010 Feb; 57(2):39-42. PubMed ID: 20189894
[No Abstract] [Full Text] [Related]
14. Increased prevalence of gallbladder polyps in acromegaly.
Annamalai AK; Gayton EL; Webb A; Halsall DJ; Rice C; Ibram F; Chaudhry AN; Simpson HL; Berman L; Gurnell M
J Clin Endocrinol Metab; 2011 Jul; 96(7):E1120-5. PubMed ID: 21543430
[TBL] [Abstract][Full Text] [Related]
15. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
Jallad RS; Musolino NR; Salgado LR; Bronstein MD
Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
[TBL] [Abstract][Full Text] [Related]
16. Dynamic tests and basal values for defining active acromegaly.
Tzanela M
Neuroendocrinology; 2006; 83(3-4):200-4. PubMed ID: 17047383
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic value of the acid-labile subunit in acromegaly: evaluation in comparison with insulin-like growth factor (IGF) I, and IGF-binding protein-1, -2, and -3.
Arosio M; Garrone S; Bruzzi P; Faglia G; Minuto F; Barreca A
J Clin Endocrinol Metab; 2001 Mar; 86(3):1091-8. PubMed ID: 11238491
[TBL] [Abstract][Full Text] [Related]
18. The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly.
Bhayana S; Booth GL; Asa SL; Kovacs K; Ezzat S
J Clin Endocrinol Metab; 2005 Nov; 90(11):6290-5. PubMed ID: 16118335
[TBL] [Abstract][Full Text] [Related]
19. Clinical features and therapeutic outcomes of 65 patients with acromegaly at Tokyo Women's Medical University.
Fukuda I; Hizuka N; Murakami Y; Itoh E; Yasumoto K; Sata A; Takano K
Intern Med; 2001 Oct; 40(10):987-92. PubMed ID: 11688841
[TBL] [Abstract][Full Text] [Related]
20. Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up.
Dimaraki EV; Jaffe CA; DeMott-Friberg R; Chandler WF; Barkan AL
J Clin Endocrinol Metab; 2002 Aug; 87(8):3537-42. PubMed ID: 12161471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
